Barclays Lowers Teladoc Health (NYSE:TDOC) Price Target to $20.00

Teladoc Health (NYSE:TDOC) had its price objective lowered by equities researchers at Barclays from $25.00 to $20.00 in a report released on Friday, Benzinga reports. The brokerage presently has an “overweight” rating on the health services provider’s stock. Barclays‘s target price would indicate a potential upside of 53.73% from the company’s previous close.

TDOC has been the topic of several other research reports. Truist Financial dropped their target price on Teladoc Health from $23.00 to $17.00 and set a “hold” rating on the stock in a report on Wednesday, March 6th. Citigroup dropped their price objective on Teladoc Health from $21.00 to $19.00 and set a “neutral” rating on the stock in a report on Wednesday, February 21st. Needham & Company LLC restated a “hold” rating on shares of Teladoc Health in a research note on Friday. Canaccord Genuity Group lowered their price target on Teladoc Health from $28.00 to $25.00 and set a “buy” rating for the company in a report on Friday. Finally, DA Davidson cut their price objective on shares of Teladoc Health from $22.00 to $18.00 and set a “neutral” rating on the stock in a report on Wednesday, February 21st. Eleven analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat.com, Teladoc Health currently has a consensus rating of “Hold” and an average target price of $19.67.

Teladoc Health Stock Performance

TDOC stock opened at $13.01 on Friday. The business’s fifty day moving average price is $14.85 and its 200 day moving average price is $17.72. Teladoc Health has a 12-month low of $12.65 and a 12-month high of $30.41. The company has a current ratio of 3.54, a quick ratio of 3.47 and a debt-to-equity ratio of 0.66.

Teladoc Health (NYSE:TDOC) last posted its quarterly earnings results on Thursday, April 25th. The health services provider reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.47) by ($0.02). The business had revenue of $646.13 million during the quarter, compared to analyst estimates of $637.31 million. Teladoc Health had a negative return on equity of 10.11% and a negative net margin of 8.90%. The business’s revenue was up 2.7% on a year-over-year basis. During the same quarter last year, the firm earned ($0.37) EPS. On average, equities research analysts expect that Teladoc Health will post -1.06 EPS for the current year.

Insider Buying and Selling

In related news, CAO Richard J. Napolitano sold 3,765 shares of Teladoc Health stock in a transaction dated Monday, March 4th. The shares were sold at an average price of $14.52, for a total value of $54,667.80. Following the sale, the chief accounting officer now directly owns 18,077 shares in the company, valued at approximately $262,478.04. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. In other news, CAO Richard J. Napolitano sold 3,765 shares of the firm’s stock in a transaction on Monday, March 4th. The stock was sold at an average price of $14.52, for a total transaction of $54,667.80. Following the transaction, the chief accounting officer now directly owns 18,077 shares of the company’s stock, valued at $262,478.04. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Laizer Kornwasser sold 7,882 shares of the firm’s stock in a transaction dated Friday, February 2nd. The shares were sold at an average price of $19.18, for a total transaction of $151,176.76. Following the transaction, the insider now directly owns 57,223 shares in the company, valued at approximately $1,097,537.14. The disclosure for this sale can be found here. Insiders sold a total of 135,441 shares of company stock worth $2,038,251 in the last three months. 1.63% of the stock is owned by insiders.

Hedge Funds Weigh In On Teladoc Health

Institutional investors have recently bought and sold shares of the stock. ICA Group Wealth Management LLC acquired a new position in Teladoc Health in the 4th quarter worth approximately $28,000. Hexagon Capital Partners LLC lifted its holdings in shares of Teladoc Health by 204.4% in the fourth quarter. Hexagon Capital Partners LLC now owns 1,586 shares of the health services provider’s stock valued at $34,000 after purchasing an additional 1,065 shares in the last quarter. RIA Advisory Group LLC acquired a new stake in shares of Teladoc Health in the fourth quarter worth $36,000. GAMMA Investing LLC acquired a new stake in shares of Teladoc Health in the fourth quarter worth $41,000. Finally, Principal Securities Inc. purchased a new position in shares of Teladoc Health during the fourth quarter valued at $45,000. Hedge funds and other institutional investors own 76.82% of the company’s stock.

Teladoc Health Company Profile

Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.